US2013190839A1PendingUtilityA1

Drug delivery using a sacrificial host

44
Assignee: RAPSEY JANEPriority: Jan 20, 2012Filed: Jan 20, 2012Published: Jul 25, 2013
Est. expiryJan 20, 2032(~5.5 yrs left)· nominal 20-yr term from priority
Inventors:Jane RapseyMartin SvehlaPeter SchullerChristopher Robert Miller
A61L 27/18A61P 39/06A61P 31/00A61P 29/00A61L 27/54A61F 2250/0067A61L 2300/602A61N 1/0541A61L 2430/14A61L 27/58A61F 11/00A61L 27/20
44
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

An implantable drug-doped component, e.g., a cochlear implant, includes host material, a host-embedded drug and a sacrificial material integrated with the host. Upon exposure of the sacrificial material to a solvent, e.g., perilymph fluid, voids in the host are created which facilitate release of the drug. The host can be, e.g., polysiloxane or silicone rubber. The sacrificial material, e.g., can be a glucose monomer, sugar, cyclodextrin, a salt, a bioresorbable material, hyaluronic acid, polyurethane, polyester, polyamide, polyvinyl alcohol, polyacrylic acid, etc. Alternatively, the sacrificial material can be the host, and can facilitate release of the drug through changing a property of the sacrificial material, e.g., by exposing the component to an ethanol wash. For a cochlear implant, e.g., the drug doped material can be applied to a non-stimulating surface of the electrode array.

Claims

exact text as granted — not AI-modified
1 . An implantable drug-doped component comprising:
 a host material,   a drug embedded in the host material, and   a sacrificial material integrated with the host material;   wherein the sacrificial material facilitates the release of the embedded drug from the drug-doped component.   
     
     
         2 . The implantable drug-doped component of  claim 1  wherein:
 the sacrificial material facilitates the release of the drug from the drug-doped component through the creation of voids in the host material upon dissolution of the sacrificial material upon contact with a solvent. 
 
     
     
         3 . The implantable drug-doped component of  claim 2  wherein:
 the solvent is perilymph fluid. 
 
     
     
         4 . The implantable drug-doped component of  claim 2  wherein:
 the contact with a solvent is at least one of: during surgery, and upon implant of the component in a recipient. 
 
     
     
         5 . The implantable drug-doped component of  claim 2  wherein:
 the host material is a polysiloxane. 
 
     
     
         6 . The implantable drug-doped component of  claim 2  wherein:
 the host material is a silicone rubber. 
 
     
     
         7 . The implantable drug-doped component of  claim 2  wherein:
 the drug at least one material from the group comprising: an anti-inflammatory, a growth factor, an antibody, an anti-oxidant, an antibiotic, and a corticosteroid. 
 
     
     
         8 . The implantable drug-doped component of  claim 2  wherein:
 the sacrificial material is at least one of: a glucose monomer, a sugar. 
 
     
     
         9 . The implantable drug-doped component of  claim 2  wherein:
 the sacrificial material is a cyclodextrin. 
 
     
     
         10 . The implantable drug-doped component of  claim 2  wherein:
 the sacrificial material is a material that is at least one of dissolvable and re-sorbable in the environment of an implant site. 
 
     
     
         11 . The implantable drug-doped component of  claim 2  wherein:
 the sacrificial material is a salt. 
 
     
     
         12 . The implantable drug-doped component of  claim 2  wherein:
 the sacrificial material is a bioresorbable material. 
 
     
     
         13 . The implantable drug-doped component of  claim 2  wherein:
 the sacrificial material is at least one material from the group comprising: hyaluronic acid, polyurethane, polyester, polyamide, polyvinyl alcohol, and polyacrylic acid. 
 
     
     
         14 . The implantable drug-doped component of  claim 1  wherein:
 the sacrificial material facilitates the release of the drug from the drug-doped component through changing a property of the sacrificial material. 
 
     
     
         15 . The implantable drug-doped component of  claim 14  wherein:
 the change in property has been brought about by exposing the drug-doped component to an ethanol wash. 
 
     
     
         16 . A cochlear implant comprising:
 an electrode array comprising a most basal electrode contact; and   a drug-doped component comprising:
 a host material, 
 a drug embedded in the host material, and 
 a sacrificial material integrated with the host material; 
 wherein the sacrificial material facilitates the release of the embedded drug from the drug-doped component. 
   
     
     
         17 . The cochlear implant of  claim 16  wherein:
 the sacrificial material facilitates the release of the drug from the drug-doped component through the creation of voids in the host material upon dissolution of the sacrificial material upon contact with a solvent. 
 
     
     
         18 . The cochlear implant of  claim 17  wherein:
 the solvent is perilymph fluid. 
 
     
     
         19 . The cochlear implant of  claim 17  wherein:
 the contact with a solvent is at least one of: during surgery, and upon implant of the component in a recipient. 
 
     
     
         20 . The cochlear implant of  claim 17  wherein:
 the host material is a polysiloxane. 
 
     
     
         21 . The cochlear implant of  claim 17  wherein:
 the host material is a silicone rubber. 
 
     
     
         22 . The cochlear implant of  claim 17  wherein:
 the drug at least one material from the group comprising: an anti-inflammatory, a growth factor, an antibody, an anti-oxidant, an antibiotic, and a corticosteroid. 
 
     
     
         23 . The cochlear implant of  claim 17  wherein:
 the sacrificial material is at least one of: a glucose monomer, a sugar. 
 
     
     
         24 . The cochlear implant of  claim 17  wherein:
 the sacrificial material is a cyclodextrin. 
 
     
     
         25 . The cochlear implant of  claim 17  wherein:
 the sacrificial material is a material that is at least one of dissolvable and re-sorbable in the environment of an implant site. 
 
     
     
         26 . The cochlear implant of  claim 17  wherein:
 the sacrificial material is a salt. 
 
     
     
         27 . The cochlear implant of  claim 17  wherein:
 the sacrificial material is a bioresorbable material. 
 
     
     
         28 . The cochlear implant of  claim 17  wherein:
 the sacrificial material is at least one material from the group comprising: hyaluronic acid, polyurethane, polyester, polyamide, polyvinyl alcohol, and polyacrylic acid. 
 
     
     
         29 . The cochlear implant of  claim 17  wherein:
 the sacrificial material facilitates the release of the drug from the drug-doped component through changing a property of the sacrificial material. 
 
     
     
         30 . The cochlear implant of  claim 29  wherein:
 the change in property has been brought about by exposing the drug-doped component to an ethanol wash. 
 
     
     
         31 . The cochlear implant of  claim 17  wherein:
 the drug doped material is applied to a non-stimulating surface of the electrode array. 
 
     
     
         32 . The cochlear implant of  claim 17  wherein:
 the drug-doped material is a physical feature of the stimulating medical device. 
 
     
     
         33 . The cochlear implant of  claim 17  wherein:
 the drug-doped material is one physical feature from the group of physical features comprising: a soft tip, a ridge, and a spine. 
 
     
     
         34 . The cochlear implant of  claim 17  wherein:
 the drug-doped material is not applied on the basal side of the most basal electrode contact.

Join the waitlist — get patent alerts

Track US2013190839A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.